What the future holds for women after menopause: Where we have been, where we are, and where we want to go

Climacteric

Volumn 17, Issue , 2014, Pages 12-17

  Lobo, R A ^a  

^a Columbia University ^*  (United States)

Author keywords

Coronary Heart Disease; Future; Menopause; MHT; Mortality; Personalized Medicine; Prevention

Indexed keywords

BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CONFERENCE PAPER; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HEALTH CARE NEED; HORMONAL THERAPY; HUMAN; LONGEVITY; PERSONALIZED MEDICINE; POSTMENOPAUSE; QUALITY OF LIFE; CARDIOVASCULAR DISEASES; DRUG EFFECTS; HISTORY; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT; TRENDS; WOMEN'S HEALTH;

ESTROGEN; GESTAGEN;

CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PROGESTINS; QUALITY OF LIFE; RISK ASSESSMENT; WOMEN'S HEALTH;

EID: 84911385799     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.944497     Document Type: Conference Paper

References (53)

1. http://www.census.gov/population
2. www.pharmamedtechbiocom/publications/the-pink-sheet/52/019
3. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63
4. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-8
5. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37
6. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59
7. Anderson GL, Chlebowski RT, Argaki AK, et al. Conjugatedequine estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomized placebo-controlled trial. Lancet Oncol 2012;13:476-86
8. Ross RK, Pike MC, H enderson BE, Mack TM, L obo RA. Stroke prevention anDoestrogen replacement therapy. Lancet 1989;I:505
9. Mendelsohn ME, Karas RH. Mechanisms of disease: The protective effects of estrogeNon the cardiovascular system. N Engl J Med 1999;340:1801-11
10. Mendelsohn M E, K aras R H. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-7
11. Lobo R A, Whitehead M. T oo much of a good thing?. Use of progestogens in the menopause: An international consensus statement. Fertil Steril 1989;51:229-31
12. Hulley S, G rady D, B ush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13
13. Herrington D M, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9
14. Writing Group for the Women' s Health Initiative Investigators. Risks and benefi ts of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
15. Burger HG, MacLennan AH, Huang K-E, Castelo-Branco C. Evidence-based assessment of the impact of the WHI on women's health. Climacteric 2012;15:281-7
16. NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk and lack of overall benefit. South Med J 2002;95:795-7
17. Ettinger B, Wang S M, L eslie R S, et al. E volution of postmenopausal hormone therapy between 2002 and 2009. Menopause 2012;19:610-15
18. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol 2012;120:595-603
19. Gompel A, P lu-Bureau G. I s the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy?. Ann NY Acad Sci 2010;1205:268-76
20. Stevenson JC, Hodis HN, Pickar JH, Lobo RA. Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis 2009;207:336-40
21. Chlebowski RT, H endrix S L, Langer R D, et al. WHI Investigators. Influence of estrogen plus progestiNon breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-53
22. Anderson G L, C hlebowski R T, Rossouw J E. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen and progestin. Maturitas 2006;55:107-15
23. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugatedequine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57
24. Hsia J, Langer R D, Manson JE, et al. Conjugatedequine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-65
25. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77
26. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger anDolder women. A meta-analysis. J Gen Intern Med 2006;21:363-6
27. Salpeter S R, Cheng J, Thabane L, B uckley N S, S alpeter E E. B ayesian meta-analysis of hormone therapy and mortality in younger post-menopausal women. Am J Med 2009;122:1016-22
28. LaCroix A Z, C hlebowski R T, M anson J E, et al.; WHI Investigators. Health outcomes after stopping conjugatedequine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-14
29. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention andextended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353-68
30. de Villiers T J, P ines A, P anay N, et al.;International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316-37
31. Islam S, Liu Q, Chines A, Hetzer E. Trend in incidence of osteoporosis- related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000-2005. Menopause 2009;16:77-83
32. Karim R, Dell RM, Greene D F, Mack WJ, Gallagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011;18:1172-7
33. Sarrel P M, N jike V, V inante V, K atz D L. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women age 50 to 59. Am J Pub Health 2013;103:1583-8
34. Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: A randomized trial. Ann Intern Med 2014 July 29. Epub aheaDof print
35. Hodis H. U pdate on ELITE. P resented at the 1 4th World Congress on Menopause, Cancun, Mexico, May 1-4, 2014
36. Schierbeck IL, R enmark L, T ofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ 2012;345:e6409
37. Santen RJ, Allred D C, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientifi c statement. J Clin Endocrinol Metab 2010;95(7 Suppl 1):s1-66
38. US National Safety Council: w ww.nsc.org
39. Bolland MJ, B arber P A, Doughty R N, et al. V ascular events in healthy older women receiving calcium supplementation: randomized controlled trial. BMJ 2008;336:262-6
40. Santen RJ, Kronenberg HM, Melmed S, et al. Endocrine responsive cancer. In Williams Textbook of Endocrinology, 11th edn. Philadelphia: Saunders Elsevier, 2008 :1764
41. Robson M, Offi t K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 2007;357:154-62
42. Marie-Genica Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk. Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy. Int J Cancer 2010;126:2935-46
43. Hein R, Flesch-Janys D, Dahmen N, et al. A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapYuse: a two-stage design with replication. Breast Cancer Res 2013;138:529-42
44. Ryan J, Canonico M, Carcaillon L, et al. Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study. PLoS One 2012;7:e34112
45. Bouligand J, Cabaret O, Canonico M, et al. Effect of NFE2L2 genetic polymorphism on the association betweeNoral estrogen therapy and the risk of venous thromboembolism in postmenopausal women. Clin Pharmacol Ther 2011;89:60-4
46. Canonico M, B ouaziz E, Carcaillon L, et al. S ynergism betweeNoral estrogen therapy and cytochrome P450 3A5∗1 allele on the risk of venous thromboembolism among postmenopausal women. J Clin Endocrinol Metab 2008;93:3082-7
47. Ryan J, Ancelin M L. Polymorphisms of estrogen receptors and risk of depression: therapeutic implications. Drugs 2012;72:1725-38
48. Yip VL, Pirmohamed M. Expanding role of pharmacogenomics in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2013;13:151-62
49. Herrington DM, Howard TD, Hawkins GA, et al. Estrogenreceptor polymorphisms andeffects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002;346:967-74
50. Lobo R A, D avis S R, De Villiers T J, et al. P revention of diseases after menopause. Climacteric 2014 June 27. Epub aheaDof print
51. Komm B S, Mirkin S, Jenkins S N. Development of conjugatedestrogens/bazedoxifene, the fi rst tissue selective estrogen complex (TSEC) for management of menopausal hot fl ashes and postmenopausal bone loss. Steroids 2014 June 14. Epub aheaDof print
52. Bagger Y Z, Tanko L B, A lexandersen P, et al. T wo to three years of hormone replacement treatment in healthy women have longterm preventive effects on bone mass anDosteoporotic fractures: the PERF study. Bone 2004;34:728-35
53. Bagger YZ, Tanko LB, Alexandersen P, et al. Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause 2005;12:12-17